On November 28, 2023, the evaluation results of Jiangsu Province’s unicorn enterprises and potential unicorn enterprises were released. With its technological innovation capabilities in the field of medical devices, Weiweisi Medical was successfully selected as a potential unicorn enterprise in Jiangsu in 2023.

Weiweisi was successfully selected

A potential unicorn enterprise in Jiangsu Province in 2023

As the reserve force of unicorn enterprises, potential unicorn enterprises are typical representatives of backbone technology enterprises, and have played an important role in leading technological innovation, opening up new fields and new tracks, and shaping new momentum and new advantages for development.

Weiweisi Medical has been on the list of potential unicorns at the provincial and municipal levels for many times, and was listed as a potential unicorn in China in June 2023.

VIS Medical Technology

VIS has been listed on the provincial, municipal and national potential unicorn lists many times:

In June 2023, it was selected as a potential unicorn in China;

Selected as a unicorn training enterprise in Suzhou in 2022

Selected as a “potential unicorn enterprise” in Jiangsu High-tech Industrial Development Zone in 2021

Build a complete ventricular arrhythmia product system

Meet clinical and market needs

Founded in 2019, VIS is an innovative device service platform company focusing on the research and development of cardiac rhythm management medical devices and patient rhythm data services. In just 4 years, the company successfully obtained two NMPA registration certificates for automatic external defibrillators (AEDs).

In August this year, VIS’s self-developed Palm AED was officially launched. The product breaks the core technology barriers, the front size is about the size of a smartphone, and the weight is less than 700g, successfully creating a mobile AED scene. Through the integrated and coordinated layout of its fixed-position AED, mobile AED, and drone AED, Vivis has pioneered the “air-ground integrated” AED three-dimensional rescue solution, which will significantly improve the efficiency of emergency treatment and the coverage efficiency of AED in my country.

Another core product of the company, WCD, mainly provides continuous protection for patients at high risk of short-term sudden cardiac death during the wearing period. It has entered the green channel for innovative medical device review in January 2021 and has now entered the human clinical stage.

In August 2022, Vivis was successfully selected as the AI ​​medical device innovation task unveiling unit with its “wearable automatic external defibrillator (WCD) and sudden death risk artificial intelligence assessment system”, becoming the main body of the innovation task, and is expected to break the import monopoly and fill the domestic gap.

In the future, Vivis Medical will extend the development of the world’s first multi-parameter sudden death risk assessment system through the promotion of ventricular arrhythmia wearable series products and remote data service management. Through this system, Vivis will lead the passive treatment of sudden cardiac death to the precise treatment of ventricular arrhythmia rhythm management combined with prevention and treatment.
The 14th Five-Year Plan clearly points out that it is necessary to achieve breakthroughs in the core technologies of high-end medical equipment and accelerate the promotion of import substitution. Vives Medical will continue to focus on the key core technologies of cardiac rhythm management to inject stronger impetus into accelerating the realization of import substitution of high-end medical equipment and realizing “Healthy China”.